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Background: Antenatal corticosteroids administered to women at risk of preterm birth is an intervention which has
been proved to reduce the risk of respiratory distress syndrome, intraventricular hemorrhage, and neonatal
mortality. There is a significant gap in the literature regarding the prevalence of the use of antenatal corticosteroids
in Latin American countries and the attitudes and opinions of providers regarding this practice. The aim of this
study was to assess the knowledge, attitudes and practices of health care providers regarding the use of antenatal
corticosteroids in women at risk of preterm birth in Latin America.
Methods: This was a multicenter, prospective, descriptive study conducted in maternity hospitals in Ecuador, El
Salvador, Mexico and Uruguay. Physicians and midwives who provide prenatal care or intrapartum care for women
delivering in the selected hospitals were approached using a self-administered questionnaire. Descriptive statistics
was used.
Results: The percentage of use of ACT in threatened preterm labour (TPL) reported by providers varies from 70% in
Mexico to 97% in Ecuador. However, 60% to 20% of the providers mentioned that they would not use this
medication in women at risk and would limit its use when there was a threatened preterm labour. In only one
country recommended regimens of antenatal corticosteroids are followed by around 90% of providers whereas in
the other three countries recommended regimens are followed by only 21%, 61%, 69% of providers. Around 40%
of providers mentioned that they would administer a new dose of corticosteroids again, regardless the patient
already receiving an entire regimen. Between 11% and 35% of providers, according to the countries, mentioned
that they do not have adequate information on the correct use of this medication.
Conclusions: This study shows that the use of this intervention could be improved by increasing the knowledge of
Latin American providers on its indications, benefits, and regimens.
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Preterm birth is the main cause of four million neonatal
deaths each year worldwide, 99% of which occur in low-
and middle-income countries [1].
Antenatal corticosteroid administered to women at
risk of preterm birth is an intervention which has
proved to reduce the risk of respiratory distress syn-* Correspondence: aaleman@unicem-web.org
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reproduction in any medium, provided the ordrome, intraventricular hemorrhage, and neonatal mor-
tality by 50% or more [2-4]. There is a significant gap in
the literature regarding the prevalence of the use of
antenatal corticosteroids in Latin American countries;
very few studies have been published and the results
vary widely from 4% to 37% [5-8]. In addition, there is
an urgent need to identify the cultural and geographical
factors that contribute to the lack of use in order to de-
velop specific interventions to increase the appropriate
use of antenatal steroids.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tern of the use of prenatal corticosteroids among women
delivering prematurely in hospitals in 3 Latin American
countries. Ecuador had the lowest use (34.8%), followed
by El Salvador (54.6%), and Uruguay (71%) and the ma-
ternal characteristics associated with their use [9].
The aim of this study was to assess the knowledge,
attitudes, practices and barriers of the health care provi-
ders regarding the use of antenatal corticosteroids in
women at risk of preterm birth in Ecuador, El Salvador,
Mexico and Uruguay.
Methods
Study design and population
This was a multicenter, prospective, descriptive study
targeted at health providers who provided antenatal or
intrapartum care to women delivering in hospitals in
Ecuador, El Salvador, Mexico and Uruguay.
The study was conducted in four public hospitals in
Ecuador (in the cities of Guayaquil, Cuenca, Loja and
Quito), three public and one social security hospital in
El Salvador (in the cities of San Salvador, 2 hospitals,
San Miguel and Santa Ana), one public and one social
security hospital in Mexico (in Guanajuato State), and
five public hospitals in Uruguay (in the cities of Monte-
video, Paysandú, Salto and Tacuarembó). These coun-
tries were selected as geographical examples of four sub-
areas of the region (Andean area, Central America,
North America and the South Cone, respectively.
Health-care providers who worked in the participating
facilities and had the provision of prenatal or intrapar-
tum care as their primary responsibility were included.
This included physicians, midwives, nurse practitioners
and in some cases medical students. A convenient sam-
ple of 5 health care workers per site who provided pre-
natal care or attended deliveries in the community and
referred patients to the participating hospitals were also
included.
Procedures
Hospital providers, including faculty, residents, physi-
cians, midwives and nurses were identified by the hos-
pital director and chiefs of the obstetrics and neonatal
divisions as well as by the local coordinator. Community
health care providers were identified through patients
and other providers’ referral. All eligible providers were
invited to participate by signing a consent form.
Scientific meetings, weekly rounds and “on call” sign
overs were used to approach the hospital providers.
Those who could not be reached by these means were
contacted personally.
All eligible providers were given an envelope contain-
ing an informative letter about the study, contact infor-
mation for obtaining further information, the consentform and a self administered questionnaire. All com-
pleted forms were returned in a sealed envelope.
Community providers were initially contacted by
phone or in person, either by the data collectors or the
local coordinator. The survey was delivered in person or,
if the provider accepted, by phone. Based on previous
studies from Latin American countries and the commit-
ment of the participating institutions, we anticipated a
response rate of at least 80% [10].
A self-administered questionnaire was developed by the
research team for this study. It was sent in a preliminary
version to a panel of experts (obstetrics, midwives, neona-
tologists, family doctors) from the participating hospitals.
Based upon the panel's critique, the research team built
the final instrument. The questionnaire was piloted in a
sample of providers from the participating hospitals in
each country in order to reach cultural adequacy.
The questionnaire included 45 items including ques-
tions related to socio-demographic and professional
characteristics, clinical practice characteristics, know-
ledge on the magnitude of the problem of preterm birth,
prevalence of the use of antenatal corticosteroids, atti-
tudes towards the use of antenatal corticosteroids,
current practices with respect to antenatal corticoster-
oids, knowledge on side effects and contraindications,
knowledge on types of corticosteroids, doses and fre-
quency, the moment of pregnancy when it is indicated,
common barriers to the appropriate use of antenatal
steroids and issues of providers’ opinions on the magni-
tude and importance of the topic. Some clinical situa-
tions were also posed to the providers to assess their
behaviours under these circumstances.Data management
The country coordinator from each country periodically
collected all forms from the participating hospitals. Each
form was photographed by the data management coordin-
ator with a digital camera provided by the study coordin-
ation, and then transmitted to special email accounts at
the Central Data Management Unit using the SSL (Secure
Sockets Layer) protocol, with a hosting provider digital
certificate. Access to the system was limited to authorized
individuals in each participating country and in the Cen-
tral Data Management Unit located at the Clinical and
Epidemiological Research Unit at Montevideo, Uruguay
(UNICEM), using a user name and password. The data
was entered in a secure data management system (DMS),
specifically designed for this study and fully compliant
with good clinical practices. A double data entry was per-
formed on a 15% random sample of the data forms to as-
sess quality of data entry. To preserve the confidentiality
of the participants, personal identifiers were not included
in the data forms or transmitted to the data center.
Aleman et al. Reproductive Health 2013, 10:4 Page 3 of 7
http://www.reproductive-health-journal.com/content/10/1/4Hospital data collectors signed a confidentially agreement
at the beginning of the study.
Data analysis
Sample size was calculated assuming a frequency of
around 80% on the reply to the major outcome: adminis-
tration of antenatal corticosteroids (ACT) on women with
threatened preterm labour (TPL). Assuming a frequency
of around 75% and a sample of 80 providers in each coun-
try the true value will fluctuate between 65% and 85%.
The total response rate was calculated and data on re-
fusal rate (active and passive) and other factors asso-
ciated with recruitment efforts were calculated.
A descriptive analysis of providers’ socio-demographic
and professional characteristics was performed for each
country as well as globally. A binomial 95% confidence
interval of the proportions of providers who start pre-
scribing antenatal corticosteroids before 24 weeks, be-
tween 24 to 27 weeks and between 28 to 34 weeks for
each country was reported. In order to make the com-
parison of the proportions of providers that used ante-
natal corticosteroids in different obstetric situations even
when women did not have a threatened preterm labour
but they were at risk of delivering preterm, Marascuilo
procedure was used. This procedure enables to simul-
taneously test the differences of all pairs of proportions.
This study was approved by the Institutional Review
Board in each country. (IORG0002991 Facultad de
Medicina, Universidad de la Republica del Uruguay,
IRB00002438 - Universidad Central del Ecuador, Facultad
de Ciencias Medicas del El Salvador, IRB00004952 - Hos-
pital Nacional Rosales de Ecuador and Bioethical Commit-
tee, Facultad de Enfermería y Obstetricia de Celaya de la
Universidad de Guanajuato, Mexico).
Results and discussion
A total of 353 health providers answered the question-
naire. Older ages were seen in Ecuadorian providers. In
all the countries the majority of them were medical doc-
tors. Uruguay shows the highest proportion of midwives
(21.5%). Years assisting deliveries varied between 5 and
14 among the countries and the mean number of deliv-
eries assisted by month by the professional varies from
4.5 in Mexico to 20 in El Salvador (Table 1). The re-
sponse rate was 98% (59/60) in Mexico (Celaya), 96%
(109/113) in El Salvador, 65% (121/186) in Uruguay and
48% (64/133) in Ecuador.
The majority of providers started providing ACT be-
yond 28 weeks of amenorrhea with the exception of
Uruguay. (Table 2).Most Uruguayan professionals (80.
2%) reported the prescription of ACT between 24 to
27 weeks of gestational age.
The percentage of providers that reported prescribing
antenatal corticosteroids between 24 to 27 weeks wasalso statistically different between El Salvador and
Mexico (51% vs 19.5% p<0, 05).
In El Salvador, Mexico and Ecuador the most ACT
used was Betametasone, while in Uruguay Dexameta-
sone was exclusively used. Two doses of 12 mg of Beta-
metasone were used by 90% of providers in El Salvador
and 60% and 21% in Ecuador and Mexico, respectively.
61% of the Uruguayan providers used 4 doses of 6 mg of
dexametasone (data not shown).
The percentage of providers that answered that they
administered antenatal corticosteroids on women with
threatened preterm labor (TPL) varied from 70% in
Mexico to 97% in Ecuador. Situations that diminished the
frequency of administration on women with TPL varied
between countries. In Mexico a marked reduction of corti-
costeroids provision by providers was mentioned when
women presented complications such as diabetes, hyper-
tension and any infection. A similar but less marked pat-
tern was shown in Ecuador. In El Salvador and Uruguay
minor changes in the number of providers limiting admin-
istration due to a diversity of events was seen (Table 3).
Providers were asked about their behaviour in situa-
tions leading to the provision of ACT in the absence of
TPL (Table 4). In general with small variations the provi-
ders in the countries followed similar behaviours. ACTs
are mentioned to be frequently provided in multiple
pregnancies, in preterm premature rupture of mem-
branes, and in haemorrhage in the second half of preg-
nancy. Previous preterm birth and preeclampsia without
TPL was mentioned as an indication of ACT by more
than 50% of the professionals in all the countries. Other
indications leading to ACT administration but with less
frequency are: intrauterine growth restriction, hyperten-
sion, diabetes, and urinary infection (Table 4).
Providers were faced with different clinical situations
to assess their behavior. More than a quarter of them in
El Salvador and Ecuador and more than half of them in
Mexico replied that they would not give ACT to a
healthy woman with a gestational age of 27 weeks, hos-
pitalized due to TPL, meanwhile almost all of the Uru-
guayan providers would give ACT in the same situation
(Table 5). Around two thirds of providers in El Salvador,
Ecuador and Uruguay would not give additional ACT to
the woman in this clinical situation after discharge.
However, in the case of this woman being hospitalized
again, around 40% of providers in these three countries
would give an additional ACT dose.
Between 20% and 57% of the providers according to
the countries replied that they considered there to be
barriers in the administration of ACT. One of them
is availability of ACT with variations among countries
from 7.5% to 32% (Table 6). From 9% to 33% according
to the countries mentioned that one barrier is the
fear or doubt of the side effects of ACT and similar
Table 1 Socio-demographic characteristics of respondents
El Salvador (N=109) Mexico (N=59) Ecuador (N=64) Uruguay (N=121)
n (%) n (%) n (%) n (%)
Age (mean and S.D.) 33.8 (8.3) 42.0 (11.7) 44.3 (13.3) 38.1 (8.4)
Gender (Male) 50 (45.9) 36 (61.0) 36 (56.3) 50 (41.3)
Profession
Medical Doctor 103 (94.5) 53 (89.8) 60 (93.8) 95 (78.5)
Medicine Student 6 (5.5) 0 (0.0) 0 (0.0) 0.0 (0.0)
Midwives 0 (0.0) 6 (10.2) 1 (1.6) 26 (21.5)
Nurse 0 (0.0) 0 (0.0) 3 (4.7) 0.0 (0.0)
University affiliation 18 (16.5) 10 (16.9) 25 (39.1) 40 (33.1)
Years assisting deliveries (median and IQR) 5 (3-8) 14 (5.3 – 23.8) 13 (4-26) 9 (3-14)
Deliveries assisted by month (median and IQR) 20 (10-30) 4.5 (2 -10) 8 (4-25) 12 (7.5-20)
IQR: Inter Quartile range.
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the correct use of ACT. They already mentioned that some
barriers are due to the users such as economic barriers and
women´s misinformation about the correct use of ACT.
This study shows that in four Latin American coun-
tries a vast majority of providers replied that they use
ACT in women in TPL varying from 70% in Mexico to
97% in Ecuador. However, in some situations with no
contraindications of the use of ACT providers, fluctuat-
ing from 20% to 60%, providers said that they will limit
the use of ACT on women with TPL. In only one coun-
try recommended regimens of ACT is followed by
around 90% of providers whereas in the other three
countries recommended regimen is followed only by 21,
61, and 69% of providers. Around 40% of providers men-
tioned that they would administer a new dose of ACT
again, regardless of the patient already receiving an en-
tire regimen. Between 11% and 35% of providers accord-
ing to the countries mentioned that they do not have
good information on the correct use of ACT.
The reason as to only dexamethasone being used in
Uruguay is because bethametasone is not available to be
used for the prevention of preterm birth newborn com-
plications in this country.
Even though the participating countries were selected
to represent 4 main Latin American sub regions, and the
participating hospitals are reference institutions in their
countries, because they were not randomly selected
we cannot infer that the observed pattern of use isTable 2 Use of Corticosteroids reported by the providers
El Salvador (N=109) Me
n/N (%) [95% CI] n/N (%
Start prescribing antenatal
corticosteroids
Before 24
weeks
1/102 (1.0) [0.0 – 5.3] 4/41 (
24 to 27 52/102 (51.0) [40.9 – 61.0] 8/41 (1
28 to 34 49/102 (48.0) [38.0 – 58.2] 29/41 (7representative of other hospitals in those countries.
However, because we selected influential reference hos-
pitals in the countries’ capital cities, we believe that this
might increase the likelihood that the use of corticoster-
oids in other hospitals may be similar.
Regardless of around 90% of providers reporting that
they use ACT in TPL, information obtained from
women having preterm births in the same hospitals
showed figures of 34.8%, 54.6%, and 71% in Ecuador, El
Salvador and Uruguay, respectively of ACT use [9]. Rea-
sons explaining such discrepancy needs to be subject of
analysis and actions to improve the reception of ACT on
pregnancies that finally end in preterm birth.
Providers´ lack of knowledge on the use of ACT
appears in this survey. Many providers limited the use of
ACT under certain obstetrics conditions without any
support from the literature justifying such behavior.
There is also a disparity in the doses and frequencies of
ACT. While in one country the vast majority of provi-
ders mentioned the prescription of the doses recom-
mended in the literature and in the international and
national guidelines, in other countries between 40% and
80% of providers did not mention this correct regimen.
There is also no evidence that repeated doses of ACT
are of benefit, but 60% of providers faced with a clinical
situation said that they would repeat the administration
after an episode of ATL [11].
There are many barriers considered by the providers
that could be solved by better availability of the drugxico (N=59) Ecuador (N=64) Uruguay (N=121)
) [95% CI] n/N (%) [95% CI] n/N (%) [95% CI]
9.8) [2.7 – 23.1] 0/60 (0.0) [0.0 – 6.0] 1/101 (1.0) [0.0 – 5.4]
9.5) [8.8 – 34.9] 21/60 (35.0) [23.1 – 48.4] 81/101 (80.2) [71.1 – 87.5]
0.7) [54.5 – 83.9] 39/60 (65.0) [51.6 – 76.9] 19/101 (18.8) [11.7 – 27.8]
Table 3 Frequency of providers that use antenatal corticosteroids in threaten preterm labor
El Salvador
(N=109)
Mexico
(N=59)
Ecuador
(N=64)
Uruguay
(N=121) Differences between Countries*
n/N (%) n/N (%) n/N (%) n/N (%)
Women with threatened
preterm labor (TPL)
100/106 (94.3) 35/50 (70.0) 58/60 (96.7) 106/121 (87.6) - Mexico differs from El Salvador and Ecuador
Women with TPL and
Rupture of membranes 100/105 (95.2) 28/45 (62.2) 49/59 (83.1) 105/121 (86.8) -Mexico differs from El Salvador and Uruguay
Diabetes 90/101 (89.1) 21/45 (46.7) 36/56 (64.3) 97/121 (80.2)
-Mexico differs from El Salvador and
Ecuador - El Salvador differs from Ecuador
Hypertension 97/102 (95.1) 23/43 (53.5) 40/55 (72.7) 100/121 (82.6)
- El Salvador differs from the rest Mexico
differs from Uruguay
Multiple pregnancy 104/107 (97.2) 38/49 (77.6) 58/60 (96.7) 106/121 (87.6)
- El Salvador differs from Mexico and Uruguay
- Mexico differs from Ecuador
Upper urinary infection 94/104 (90.4) 18/41 (43.9) 38/56 (67.9) 99/121 (81.8)
- El Salvador differs from Mexico and Ecuador
- Mexico differs from Uruguay
Lower urinary infection 88/103 (85.4) 17/41 (41.5) 43/56 (76.8) 100/121 (82.6) - Mexico differs from the rest
Asymptomatic bacteriuria 86/102 (84.3) 16/41 (39.0) 46/57 (80.7) 99/121 (81.8) - Mexico differs from the rest
Chorioamnionitis 90/105 (85.7) 18/41 (43.9) 28/57 (49.1) 95/121 (78.5)
- El Salvador and Uruguay differ
from Mexico and Ecuador
*The Marascuilo test was used to test the differences between countries.
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on the benefits of ACT.
As previously stated, ACT is one of the most beneficial
interventions in reducing neonatal complications due to
preterm birth including neonatal death. In spite of this,
its use in low-and-middle income countries is lower
than expected [5-9].
Although there were national and institutional guide-
lines in the participating countries at the time of the sur-
vey, they were in some cases not updates and not clear.Table 4 Providers prescribing antenatal corticosteroids in sev
preterm labor
El Salvador
(N=109)
Mexico
(N=59)
n/N (%) n/N (%
Multiple pregnancy 92/106 (86.8) 33/44 (75
Preterm premature rupture of membranes 98/106 (92.5) 30/43 (69
Haemorrhage in the second half of pregnancy 91/106 (85.8) 23/37 (62
Pre-eclampsia 82/104 (78.8) 22/42 (52
Intrauterine growth restriction 49/101 (48.5) 17/40 (42
Previous preterm birth 70/105 (66.7) 24/38 (63
Upper urinary infection 46/101 (45.5) 16/39 (41
Hypertension 47/100 (47.0) 16/39 (41
Diabetes 36/98 (36.7) 10/39 (25
Lower urinary infection 32/99 (32.3) 16/38 (42
Asymptomatic bacteriurua 29/99 (29.3) 8/36 (22
*The Marascuilo test was used to test the differences between countries.They did not include a clear and direct recommendation
of use what could have influence the underuse and mis-
use of antenatal corticosteroids.
Conclusions
This study shows that the use of antenatal corticoster-
oids should be improved in participating countries. In-
creasing availability of this medication at primary health
care centers seems to be a mayor strategy. On the other
hand, increasing the knowledge of Latin Americaneral obstetric situations different from a threatened
Ecuador
(N=64)
Uruguay
(N=121) Differences between Countries*
) n/N (%) n/N (%)
.0) 51/59 (86.4) 101/106 (95.3) - Mexico differs from Uruguay
.8) 46/56 (82.1) 100/106 (94.3)
- Mexico differs from El Salvador
and Uruguay
.2) 38/49 (77.6) 86/106 (81.1) - No difference between countries
.4) 30/47 (63.8) 72/106 (67.9) - El Salvador differs from Mexico
.5) 29/48 (60.4) 70/106 (66.0) - No difference between countries
.2) 36/52 (69.2) 63/106 (59.4) - No difference between countries
.0) 22/45 (48.9) 55/106 (51.9) - No difference between countries
.0) 24/44 (54.5) 36/106 (34.0) - No difference between countries
.6) 19/45 (42.2) 30/106 (28.3) - No difference between countries
.1) 21/44 (47.7) 25/106 (23.6) - Ecuador differs from Uruguay
.2) 22/43 (51.2) 22/106 (20.8)
- Ecuador differs from Mexico
and Uruguay
Table 5 Providers´ replies to theoretical clinical situations
El Salvador
(N=109)
Mexico
(N=59)
Ecuador
(N=64)
Uruguay
(N=121)
n/N (%) n/N (%) n/N (%) n/N (%)
CLI NICAL SITUATION 1
Prescribe antenatal corticosteroids to a healthy women in
a gestational age of 27 weeks who is hospitalized due to TPL
81/108 (75.0) 24/51 (47.1) 45/61 (73.8) 102/105 (97.1)
The woman is discharged after 72 hs. The TPL is arrested.
¿Which is the indication?
A doses every month 5/105 (4.8) 5/41 (12.2) 0/56 (0.0) 3/105 (2.9)
A doses every two weeks 1/105 (1.0) 1/41 (2.4) 2/56 (3.6) 1/105 (1.0)
A doses every week 24/105 (22.9) 10/41 (24.4) 8/56 (14.3) 8/105 (7.6)
No doses 68/105 (64.8) 0/41 (0.0) 40/56 (71.4) 71/105 (67.6)
Other 7/105 (6.7) 25/41 (61.0) 6/56 (10.7) 22/105 (21.0)
Prescribe antenatal corticosteroids for the same patient if
she is hospitalized again due to TPL at the gestational
age of 32 weeks
42/107 (39.3) 25/60 (41.7) 50/106 (47.2)
CLI NICAL SITUATION 2
Prescribe antenatal corticosteroids to a healthy women with
a gestational age of 25 weeks who is hospitalized due to a
rupture of membranes of 4 hours of evolution, without cervical
dilatation and signs of infection
48/108 (44.4) 21/48 (43.8) 27/61 (44.3) 82/105 (78.1)
CLI NICAL SITUATION 3
Prescribe antenatal corticosteroids to a healthy woman with two
previous preterm births at 30 and 32 weeks and with the actual
pregnancy with no complications
82/108 (75.9) 25/47 (53.2) 27/61 (44.3) 71/107 (66.4)
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ATC and improving characteristics of national and insti-
tutional guidelines are also needed interventions. The
development of clear and evidence-based recommenda-
tions and interventions to promote providers adoption
of them represent valuables strategies to be implemen-
ted. Studies developed in other developing countries
have reached the same conclusions [12,13].Table 6 Barriers for the use of corticosteroids
El Salvad
n/N
Exists barriers 60/106
HEALTH SYSTEM
Corticosteroids availability at hospitals 33/103
Corticosteroids availability at primary health care centers 57/104
Availability at night hours 22/100
PROVIDERS
Fear or doubt about the side effect of the use of corticosteroids 33/100
Misinformation about the correct use of the corticosteroids 36/103
WOMEN
Economic barriers to get corticosteroids 52/104
Lack of personnel who can apply the corticosteroids 24/101
Fear to use corticosteroids 20/102
Misinformation about the correct use of the corticosteroids 39/101Details of ethics approval
This study was approved by the Institutional Review
Board in each country.
Facultad de Medicina, Universidad de la Republica del
Uruguay, (IRB0002991) date: 2004.
Universidad Central del Ecuador (IRB00002438), date:
4th April, 2005.or (N=109) Mexico (N=59) Ecuador (N=64) Uruguay (N=121)
(%) n/N (%) n/N (%) n/N (%)
56.6 10/49 20.4 16/60 26.7 34/107 31.8
32.0 4/47 10.6 7/57 12.3 8/107 7.5
54.8 6/47 12.8 8/56 14.3 27/107 25.5
20.2 7/46 15.2 6/56 10.7 21/107 19.6
33.0 7/46 15.2 10/56 17.9 10/107 9.3
35.0 9/48 18.8 8/54 14.8 12/107 11.2
50.0 7/46 15.2 9/57 15.8 17/107 15.9
23.8 3/45 6.7 3/55 5.5 19/107 17.8
19.6 6/46 13.0 8/55 14.5 4/107 3.7
38.6 5/45 11.1 9/54 16.7 8/107 7.5
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(IRB00004952) - .date : 26th September 2006.
Comité de Bioética de la Facultad de Enfermería y
Obstetricia de Celaya de la Universidad de Guanajuato,
Mexico.
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